GlassScriptPhysician profile
Jill B Mcleod
NPI 1861704082
$5,162.65
in general payments reported to CMS, 2019-2025
27 companies · $419 in 2025
The $419 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $230 · 2021: $3,368 · 2022: $63.72 · 2023: $308 · 2024: $264 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,679.65 | 2020-2025 | |
| Abbvie INC. | $280.52 | 2019-2021 | |
| Optumhealth Care Solutions, LLC | $134.69 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Sage Therapeutics, LLC | $119.97 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $115.20 | 2019-2025 | Veozah |
| Coopersurgical, INC. | $100.76 | 2023-2025 | Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $86.48 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $74.66 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $73.94 | 2023-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Conmed Corporation | $55.56 | 2023 | Airseal |
| Pfizer INC. | $45.46 | 2019-2025 | |
| Kerecis Limited | $45.30 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Duchesnay USA Incorporated | $43.20 | 2019 | |
| Shield Therapeutics INC | $38.68 | 2023-2024 | Accrufer |
| Daiichi Sankyo INC. | $34.29 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.09 | 2019 | |
| Mylan Pharmaceuticals INC. | $28.95 | 2022 | |
| Novo Nordisk INC | $24.68 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.98 | 2019 | |
| Hydrofera LLC | $22.67 | 2025 | Leukomed Sorbact |
| Minerva Surgical, INC | $21.63 | 2025 | |
| Exeltis, USA INC. | $20.59 | 2022 | |
| Organon LLC | $16.45 | 2024 | |
| Mallinckrodt Enterprises LLC | $15.75 | 2019 | |
| Smith+Nephew, INC. | $14.37 | 2023 | Pico 14, Pico 7 |
| Agile Therapeutics, INC. | $14.13 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$583,176.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mcleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.